الفهرس 
Assessment of Venous System in Egyptian Patients with chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors Below the Age of Fifty
List of ContentsOnly 14 pages are availabe for public view
 |  | from | 117 |  |  |
| | | from | 117 | | |
Abstract
Background: chronic myeloid leukemia (CML) is characterized by abnormal
molecular mutations, abnormal expression of the BCR/ABL1 oncogene. The
BCR/ABL1 tyrosine kinase inhibitors (TKIs) are considered a gold standard of
treatment of patients with newly diagnosed CML Multiple vascular venous events are
reported in patients with CML treated with TKIs so vascular safety is an emerging
issue. Whereas imatinib exhibits a well-documented and favorable long-term safety
profile without obvious accumulation of vascular events., several types of vascular
adverse events (VAEs).
Aim: To estimate the incidence of venous insults by venous Color Doppler in patients
with CML treated with different tyrosine kinase inhibitors.
Patients and Methods: we conducted a case control study including 70 CML patients
and 50 healthy controls, cases were sub grouped into three groups’ imatinib 400,
nilotinib 800 mg and nilotinib 600 mg. all patients were assessed for venous insults
using color vascular doppler and its correlation with different TKIs.
Results: Our results showed BCR ABL level was significantly the highest level in
imatinib 400 mg group and the lowest level in nilotinib 600 mg group with p value
0.022, post-hoc study for the comparison of BCR ABL and the difference was
between imatinib and nilotinib revealed statistical difference between imatinib and
both concentrations of nilotinib in initial BCR ABL which may reflect later results of
why BCR ABL in remission was in favor for nilotinib to imatinib. Our data showed
the highest incidence of remission was reported in nilotinib group (62.7%), mean Hb
concentration was lower in patients with remission compared to non-remission BCR
ABL, while mean platelet count was higher among remission arms.
Conclusion: We finally concluded that there is no statistically significant difference
in the incidence of venous insults among patients diagnosed with chronic myeloid
leukemia treated with imatinib or nilotinib and healthy controls